×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated Vasculitis
AOL.com
The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval...
1 week ago
Amgen sponsors Rose Parade float to support blossoming of kidney disease awareness
Fierce Pharma
Amgen's marketing team has flown out of the traps in 2024,
4 months ago
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
PR Newswire
"The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and...
21 months ago
Chemocentryx presents new chemokine CXCR6 receptor antagonists
BioWorld MedTech
Chemocentryx Inc. has divulged chemokine CXCR6 receptor antagonists reported to be useful for the treatment of cancer, autoimmune hepatitis,...
6 months ago
Amgen bets on ChemoCentryx's rare disease drug in $3.7 billion deal
Reuters
Amgen Inc on Thursday agreed to buy ChemoCentryx Inc for $3.7 billion to gain access to a potential blockbuster treatment for inflammatory...
21 months ago
Amgen to Acquire ChemoCentryx for $3.7B, Bolstering Autoimmune Portfolio
Genetic Engineering and Biotechnology News
Amgen has agreed to acquire ChemoCentryx for approximately $3.7 billion, the companies said today, in a deal that expands the buyer's...
21 months ago
Immuneering Corporation (IMRX) Appoints Thomas J. Schall, Ph.D. to its Board of Directors
StreetInsider
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines...
1 month ago
Watkins Advises ChemoCentryx in its Billion Acquisition by Amgen
Latham & Watkins LLP
A multidisciplinary team represents the biopharmaceutical company commercializing and developing new medications in the transaction.
21 months ago
Chemocentryx Inc (CCXI) President and CEO Thomas J. Schall Sold $1.9 million of Shares
AOL.com
President and CEO of Chemocentryx Inc (30-Year Financial, Insider Trades) Thomas J. Schall (insider trades) sold 28772 shares of CCXI on 12/15/2020 at an...
2 months ago
Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading ...
PR Newswire
The disease awareness and the emergence of new products in the pipeline will add to the focal segmental glomerulosclerosis market growth in...
3 months ago